Literature DB >> 15063558

Review of pneumococcal conjugate vaccine in adults: implications on clinical development.

Betsy Abraham-Van Parijs1.   

Abstract

A literature review was conducted to determine if pneumococcal conjugate vaccines administered to healthy and immunocompromised adults, in comparison with the known efficacy in children, showed immunogenicity. Fifteen publications were retrieved. Clinical studies had been conducted using vaccines from different manufacturers, in different populations, using varied methodologies. No clear evidence of the superiority of the conjugate vaccine over the currently licensed polysaccharide vaccine emerged. Possible reasons for the lack of superiority and its implications on vaccine development are discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15063558     DOI: 10.1016/j.vaccine.2004.01.029

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Routine immunization of adults in Canada: Review of the epidemiology of vaccine-preventable diseases and current recommendations for primary prevention.

Authors:  Michael D Parkins; Shelly A McNeil; Kevin B Laupland
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

2.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

3.  Pneumococcal Vaccination in Adults.

Authors:  Tsering Y Sherpa; Howard L Leaf
Journal:  Curr Infect Dis Rep       Date:  2005-05       Impact factor: 3.725

Review 4.  Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice.

Authors:  Angel Vila-Corcoles; Olga Ochoa-Gondar
Journal:  Drugs Aging       Date:  2013-05       Impact factor: 3.923

5.  Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older.

Authors:  Angel Vila-Corcoles; Olga Ochoa-Gondar; Jorge A Guzmán; Teresa Rodriguez-Blanco; Elisabet Salsench; Cruz M Fuentes
Journal:  BMC Infect Dis       Date:  2010-03-18       Impact factor: 3.090

Review 6.  Advances in pneumococcal vaccines: what are the advantages for the elderly?

Authors:  Angel Vila-Córcoles
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

7.  Serotype-specific and age-dependent generation of pneumococcal polysaccharide-specific memory B-cell and antibody responses to immunization with a pneumococcal conjugate vaccine.

Authors:  Elizabeth A Clutterbuck; Sarah Oh; Mainga Hamaluba; Sharon Westcar; Peter C L Beverley; Andrew J Pollard
Journal:  Clin Vaccine Immunol       Date:  2007-11-21

8.  Immunization of aged mice with a pneumococcal conjugate vaccine combined with an unmethylated CpG-containing oligodeoxynucleotide restores defective immunoglobulin G antipolysaccharide responses and specific CD4+-T-cell priming to young adult levels.

Authors:  Goutam Sen; Quanyi Chen; Clifford M Snapper
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

9.  Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease.

Authors:  Mark T Dransfield; Moon H Nahm; Meilan K Han; Sarah Harnden; Gerard J Criner; Fernando J Martinez; Paul D Scanlon; Prescott G Woodruff; George R Washko; John E Connett; Nicholas R Anthonisen; William C Bailey
Journal:  Am J Respir Crit Care Med       Date:  2009-06-25       Impact factor: 21.405

Review 10.  Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals.

Authors:  Marta C Nunes; Shabir A Madhi
Journal:  Hum Vaccin Immunother       Date:  2012-02-01       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.